Australian Particle Therapy Clinical Quality Registry (ASPIRE) protocol (TROG 21.12): a multicentre prospective study on patients with rare tumours, treated with radiation therapy
Open Access
Abstract
Introduction In 2020, the Australian Medical Services Advisory Committee (MSAC) recommended new proton beam therapy (PBT) item numbers be added to the Medicare Benefits Schedule. During the MSAC 1638 application process, MSAC recognised the uncertainties inherent in the cost-utility modelling of PBT. To address these uncertainties, MSAC proposed the establishment of a national registry with the intention to gather evidence to validate the claim of PBT’s superior toxicity outcomes and cost-effectiveness compared with conventional photon radiation therapy. Methods and analysis The Australian Particle Therapy Clinical Quality Registry is a prospective, observational, longitudinal registry collecting national data on paediatric, adolescent young adult and adult patients with rare tumours receiving any form of radiation therapy for a defined group of diseases, specified by the MSAC 1638 Public Summary Document. Eligible patients undergoing radiation therapy at participating institutions will be provided with information about the registry, including the opt-out procedure. The registry has no enrolment cap and will persist either indefinitely or until the conclusion of the study. The study design was informed by the Australian Metadata Online Repository and contains a core set of minimum data elements. Representing baseline participant demographics, assessment, diagnosis and treatment; incorporating radiation and systemic therapies, with a specific focus on long-term follow-up, treatment toxicities and specific organ-at-risk testing. Ethics and dissemination There will be no identifying data used in any reports or presentations of data. Additionally, all identifiable data will be safeguarded according to standard practices and available only to the host institution submitting the data to the registry. Aggregated data for the purposes of research will be stripped of identifiers. The registry has been approved under the National Mutual Agreement by the Central Adelaide Local Health Network Human Research Ethics Committee—HREC: 2021/HRE00394. Trial registration number Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000026729p.Keywords
Funding Information
- Hospital Research Foundation (2021/44-QA25310)
This publication has 12 references indexed in Scilit:
- Proton versus photon radiation therapy: A clinical reviewFrontiers in Oncology, 2023
- If we build it, will they come? Modeling of public hospital care requirements for the Australian Bragg Centre for Proton Therapy and ResearchAsia-Pacific Journal of Clinical Oncology, 2022
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- What are the roles and valued attributes of a Trial Steering Committee? Ethnographic study of eight clinical trials facing challengesTrials, 2016
- The physics of proton therapyPhysics in Medicine & Biology, 2015
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014
- SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical TrialsAnnals of Internal Medicine, 2013
- Basics of particle therapy I: physicsRadiation Oncology Journal, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007